Premium
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis
Author(s) -
Warren R.B.,
Griffiths C.E.M.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06880.x
Subject(s) - pharmacogenetics , psoriasis , thiopurine methyltransferase , methotrexate , azathioprine , medicine , medical prescription , pharmacology , methyltransferase , bioinformatics , dermatology , genetics , genotype , gene , biology , disease , methylation
Summary The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.